TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

Impact · against what's priced in

The updates for TG Therapeutics are marginally positive but largely reflected in the stock's recent 60% rally. While the revenue guidance raise and strong H1 sales for Briumvi provide confirmation of growth, the magnitude of the increase is modest relative to the current momentum.

TGTX+0.30

No priced-in read yet

In context

The company raised its 2026 revenue guidance to $950 million and reported strong H1 sales of $437.1 million for Briumvi, confirming high growth momentum.

Read from the article alone

• biotech
• healthcare
• pharmaceuticals
• TGTX
• drug sales
• fda
• multiple sclerosis

Search tags